AI assistant
Sending…
Xenon Pharmaceuticals Inc. — Director's Dealing 2021
Nov 17, 2021
31373_dirs_2021-11-16_8cf6a50b-ccbf-41e1-ae6c-ca4c0654a24c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Xenon Pharmaceuticals Inc. (XENE)
CIK: 0001582313
Period of Report: 2021-11-15
Reporting Person: PIMSTONE SIMON N. (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-11-15 | Common Shares | S | 17557 | $31.33 | Disposed | 210186 | Direct |
Footnotes
F1: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $31.10 to $31.85, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein
More from Xenon Pharmaceuticals Inc.
Share Issue/Capital Change
2026
Jun 3
Share Issue/Capital Change
2026
Jun 3
Share Issue/Capital Change
2026
Jun 3
Share Issue/Capital Change
2026
Jun 3
Share Issue/Capital Change
2026
Jun 3
Share Issue/Capital Change
2026
Jun 3
Share Issue/Capital Change
2026
Jun 3
Share Issue/Capital Change
2026
Jun 3
Share Issue/Capital Change
2026
Jun 3
Regulatory Filings
2026
Jun 3